AQP-004 Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93
    Alomone Labs rabbit anti aqp4
    Changes in mRNA and protein levels of Kir4.1 and <t>AQP4</t> in glyoxal-treated rMC-1 cells with or without ranibizumab. The ( a ) mRNA and ( b ) protein level of Kir4.1 in glyoxal-treated rMC-1 cells with or without ranibizumab. c Immunofluorescence of Kir4.1 in rMC-1 cells. The ( d ) mRNA and ( e ) protein level of AQP4 in glyoxal-treated rMC-1 cells with or without ranibizumab. f Immunofluorescence of AQP4 in rMC-1 cells. Data are expressed as mean ± SE (n = 8 in [a, d], n = 4 in [b, e], * P
    Rabbit Anti Aqp4, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti aqp4/product/Alomone Labs
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    rabbit anti aqp4 - by Bioz Stars, 2022-09
    93/100 stars
      Buy from Supplier

    Image Search Results


    Changes in mRNA and protein levels of Kir4.1 and AQP4 in glyoxal-treated rMC-1 cells with or without ranibizumab. The ( a ) mRNA and ( b ) protein level of Kir4.1 in glyoxal-treated rMC-1 cells with or without ranibizumab. c Immunofluorescence of Kir4.1 in rMC-1 cells. The ( d ) mRNA and ( e ) protein level of AQP4 in glyoxal-treated rMC-1 cells with or without ranibizumab. f Immunofluorescence of AQP4 in rMC-1 cells. Data are expressed as mean ± SE (n = 8 in [a, d], n = 4 in [b, e], * P

    Journal: Eye and Vision

    Article Title: Anti-VEGF therapy prevents Müller intracellular edema by decreasing VEGF-A in diabetic retinopathy

    doi: 10.1186/s40662-021-00237-3

    Figure Lengend Snippet: Changes in mRNA and protein levels of Kir4.1 and AQP4 in glyoxal-treated rMC-1 cells with or without ranibizumab. The ( a ) mRNA and ( b ) protein level of Kir4.1 in glyoxal-treated rMC-1 cells with or without ranibizumab. c Immunofluorescence of Kir4.1 in rMC-1 cells. The ( d ) mRNA and ( e ) protein level of AQP4 in glyoxal-treated rMC-1 cells with or without ranibizumab. f Immunofluorescence of AQP4 in rMC-1 cells. Data are expressed as mean ± SE (n = 8 in [a, d], n = 4 in [b, e], * P

    Article Snippet: Reagents and antibodies The primary antibodies against Kir4.1 (APC-035) and AQP4 (AQP-004) were from Alomone Lab (Jerusalem, Israel).

    Techniques: Immunofluorescence

    Protein changes of ( a ) Kir4.1, ( b ) AQP4, ( c ) GS, and ( d ) GFAP in diabetic rat retinas treated with or without ranibizumab. e Co-immunostaining of Kir4.1 and GFAP in 12-week diabetic rat retinas (Kir4.1, green; GFAP, red; DAPI, blue), scale bar: 20 μm. Data are expressed as mean ± SE (n = 7, * P

    Journal: Eye and Vision

    Article Title: Anti-VEGF therapy prevents Müller intracellular edema by decreasing VEGF-A in diabetic retinopathy

    doi: 10.1186/s40662-021-00237-3

    Figure Lengend Snippet: Protein changes of ( a ) Kir4.1, ( b ) AQP4, ( c ) GS, and ( d ) GFAP in diabetic rat retinas treated with or without ranibizumab. e Co-immunostaining of Kir4.1 and GFAP in 12-week diabetic rat retinas (Kir4.1, green; GFAP, red; DAPI, blue), scale bar: 20 μm. Data are expressed as mean ± SE (n = 7, * P

    Article Snippet: Reagents and antibodies The primary antibodies against Kir4.1 (APC-035) and AQP4 (AQP-004) were from Alomone Lab (Jerusalem, Israel).

    Techniques: Immunostaining